AzTrials
AzTrials

PsychosisTOPUSNCT07716969

TOPUS - Testing an Implemented Intervention to Reduce Duration of Untreated Psychosis

An observational study of Psychosis and Schizo Affective Disorder, run by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital at 2 sites in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study examines whether an early-detection program for psychosis can shorten the time patients remain untreated after the first appearance of psychotic symptoms, and whether such a reduction improves later functioning for people with first-episode schizophrenia. Read more about this study

Who is it for?
Ages 18 to 35 years
How many people
250 participants
Where
2 sitesDenmark
Study dates
1 Mar 2024to 31 Jul 2028
How long will I take part?
18 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: Patients are recruted within the first 9 months of their OPUS treatment in the Capital region or Region Zealand.

Who may be able to join

  • 18 or older In treatement in an OPUS treatment center in The Capital Region or Region Zealand.
  • Started OPUS treatment within the last 9 months Suspected to have a psychotic disorder within the ICD 10 Schizophrenia spectrum (DF2X, excluding schizotypal disorder and schizophrenia simplex) Able to communicate adequately regarding symptoms and functioning in Danish or English.
  • -

Who cannot join

  • IQ bellow 70 I primary diagnoses of drug or alcohol dependency

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Nikolai Albert, MD, PhD contact

+45 29925014

nikolai.albert@regionh.dk

Stephen F Austen, PhD contact

+45 23259577

stfa@regionsjaelland.dk

Denmark2 sites, 2 recruiting
  • Mental Health Centre Copenhagen

    Copenhagen, Denmark, 2900

    Nikolai Albert, MD, PhD, +45 29925014, nikolai.albert@regionh.dk

    Stephen F Austen, PhD, +45 23259577, stfa@regionsjaelland.dk

    Recruiting
  • Region Zealand Psychiatry East

    Roskilde, Denmark, 4000

    Stephen F Austin, PhD, +45 23259577, stfa@regionsjaelland.dk

    Marie L Olsen, MD, +45 22915210, malag@regionsjaelland.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Duration of Untreated Psychosis Revisited - Testing the Effect of Early Detection Services on the Duration of Untreated Psychosis. the TOPUS Study

This study examines whether an early-detection program for psychosis can shorten the time patients remain untreated after the first appearance of psychotic symptoms, and whether such a reduction improves later functioning for people with first-episode schizophrenia.

Psychosis involves symptoms such as hallucinations and delusions. When these symptoms are recognized and treatment begins, most patients improve. However, many individuals live with psychotic symptoms for months-or even longer-before receiving care. This period is known as the duration of untreated psychosis (DUP). A long DUP has repeatedly been linked to poorer long-term outcomes, but it is still unclear whether DUP itself causes worse outcomes or simply reflects different illness courses.

Read more

In Denmark, Region Zealand has implemented a large-scale early-detection effort. This includes public awareness campaigns and a specialized team that identifies people with emerging psychosis and helps them start treatment quickly. The Capital Region of Denmark provides usual care without these additional initiatives. This situation makes it possible to compare two regional systems that differ in their approach to early detection but provide the same specialized treatment once patients enter care.

The study follows a quasi-experimental design, recruiting adults (18+) who receive a first diagnosis of a schizophrenia-spectrum disorder within the OPUS early-intervention programs in the two regions. No interventions are assigned by the research team; participants receive standard clinical care. Researchers conduct interviews to establish how long psychotic symptoms were present before treatment began and to assess functioning and symptoms over a two-year follow-up period. Functioning, symptoms, cognition, and treatment factors will be examined at baseline and at follow-ups.

The study addresses three questions:

Whether early-detection efforts in Region Zealand reduce the duration of untreated psychosis compared with usual detection.

Whether a shorter duration of untreated psychosis leads to better functional and clinical outcomes fifteen months after treatment begins.

How DUP can best be defined and measured so that it reliably predicts later outcomes.

Results may provide evidence for whether early-detection services improve timely access to care and whether reducing the duration of untreated psychosis contributes to better long-term functioning. The study may also help establish clearer international standards for how DUP should be measured in both research and clinical practice.

Read the detailed description

This study investigates whether a large-scale early-detection program for psychosis implemented in one Danish health region reduces the duration of untreated psychosis (DUP) and whether a shorter DUP leads to improved clinical and functional outcomes. The project takes advantage of an existing difference between two regions in Denmark: Region Zealand has, for more than a decade, operated campaign-supported early-detection teams, whereas the Capital Region provides standard detection pathways without additional outreach. Both regions deliver identical specialized treatment once patients enter the OPUS early-intervention services. This natural difference creates a unique opportunity to evaluate the real-world impact of early-detection efforts.

Scientific Rationale

DUP refers to the time between the onset of psychotic symptoms and the start of appropriate treatment. Prolonged DUP is consistently associated with worse outcomes, including more severe symptoms and poorer functioning. However, most existing evidence comes from observational studies that cannot rule out the possibility that long DUP is simply a marker of more severe or insidiously developing illness rather than a direct causal factor. The field therefore lacks strong evidence on whether active reduction of DUP improves outcomes.

Some early-detection initiatives-most prominently the TIPS study-have demonstrated that campaigns combined with rapid-access teams can significantly reduce DUP and may influence long-term functioning. However, not all attempts to reduce DUP have succeeded, and no consensus exists on the most effective strategy. It also remains uncertain how DUP should best be defined and operationalized, as several different definitions are used in the literature.

The present study is designed to help address these gaps. It examines whether an established early-detection strategy in Region Zealand has in fact shortened DUP compared with usual detection, whether any reduction has meaningful effects on two-year outcome trajectories, and which definitions of DUP provide the most reliable predictive value.

Study Design

The project uses a quasi-experimental design with two non-overlapping recruitment areas. Participants are adults with a first diagnosis of a schizophrenia-spectrum disorder who have entered OPUS treatment in either Region Zealand (early-detection region) or the Capital Region (comparison region). No experimental intervention is delivered by the research team. All participants receive routine clinical care as determined by their local OPUS center. The research activities consist of structured assessments conducted at baseline and during follow-up.

Because patients are recruited within established treatment programs and no treatment allocation is made, the study does not involve randomization or modification of clinical care. The design instead tests whether an existing system-level initiative-public awareness campaigns, stakeholder outreach, and a specialized early-detection team-has produced measurable differences in DUP and outcomes.

Study Objectives

The project is organized around three central objectives:

Effectiveness of Early Detection (WQ1):

Determine whether the early-detection initiatives in Region Zealand reduce DUP in first-episode schizophrenia compared with the Capital Region.

Impact of DUP on Outcomes (WQ2):

Evaluate whether variation in DUP predicts fifteen months functional and psychopathological outcomes within the cohort.

Operationalization of DUP (WQ3):

Compare different definitions and measurement approaches to identify how DUP is most reliably assessed and how different operationalizations affect its predictive power.

Assessments and Data Collection

At baseline, participants complete structured clinical interviews and psychometric assessments focusing on psychopathology, functioning, premorbid adjustment, cognition, and pathways to care. The measurement of DUP is central: the study uses the Nottingham Onset Schedule (NOS) as the primary tool, and definitions distinguishing between patient-level delay ("DUP Demand"), system-level delay ("DUP Supply"), and total DUP.

To examine trajectories after treatment begins, participants are contacted at 3 and 9 months for focused follow-up assessments, and they undergo a comprehensive fifteen months evaluation of functioning, symptoms, cognition, suicidality, and treatment factors. Register-based data on education, employment, hospitalization, and family formation supplement missing or incomplete follow-up information.

Analytical Approach

Because DUP is typically skewed, analyses will apply appropriate transformations or non-parametric approaches. Comparisons between regions will adjust for relevant confounders. Functional and symptom outcomes will be evaluated using regression models, and trajectories across the fifteen month period will be explored using latent class growth analysis to identify distinct functional subgroups. Multiple imputation will be used for handling missing follow-up data.

Expected Contributions

This study is among the few to evaluate early-detection efforts under real-world conditions in a public mental-health system. By comparing two regions with stable, well-defined differences in detection practices but identical treatment programs, the design provides an opportunity to examine both the system-level impact on DUP and the clinical implications of altered detection timing.

The results are expected to address three major uncertainties in the field:

whether early-detection campaigns and outreach teams meaningfully reduce the time patients remain untreated,

whether a reduced DUP improves functional and clinical outcomes, and

how DUP should be operationalized to provide the clearest and most clinically relevant information.

Establishing the effectiveness of an already-implemented early-detection model has the potential to inform service planning in Denmark and internationally. In addition, clarifying the causal role of DUP could support future health-care strategies aimed at minimizing untreated psychosis, and the project's methodological work may contribute to consensus definitions for DUP in both clinical and research settings.

Being tested
No intervention (Observational Study)
Keywords
Duration of Untreated Psychosis, Early Detection, Psychosis, Schizophrenia
Medical subject headings
Psychotic Disorders, Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No intervention (Observational Study)Other

    Participants receive standard clinical care independent of the study. No intervention is assigned by investigators.

Study groups in NCT07716969
Study groupRoleWhat they receive
Cohort 1: Region Zealand Early-Detection CohortParticipants identified through in a region with a early-detection program, which could identify participants prior to OPUS treatment
Receives: Other: No intervention (Observational Study)
Cohort 2: Capital Region Usual-Detection CohortCohort 2: Capital Region Usual-Detection Cohort
Receives: Other: No intervention (Observational Study)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Duration of Untreated Psychosis measured with the NOS

    Measured: From start inclusion, marts 2024, to end inclusion marts 2027

  2. PSP

    Personal and Social Performance Scale

    Measured: From beginning of 15 months follow-up, May 2025, until end of follow-up, September 2028

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2026
  2. Study start1 Mar 2024
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
250 participants (estimated)
Target duration
18 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07716969
Sponsor's protocol ID
H-23040813
Acronym
TOPUS
Status last verified
Jul 2026
First submitted
16 Jul 2026
Last updated
21 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will after completion of the study be transferred in the Danish National Archives, where from they can be requested and delivered in accordance with Danish data protection laws.

Questions about this trial

What is this clinical trial studying?

An observational study of Psychosis and Schizo Affective Disorder, run by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital at 2 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nikolai Albert, MD, PhD (+45 29925014, nikolai.albert@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Duration of Untreated Psychosis measured with the NOS (time frame: From start inclusion, marts 2024, to end inclusion marts 2027). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in